Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 449 publications
Unleashing Precision Oncology in the Development of Human Epidermal Growth Factor Receptor 2-Targeted Antibody Drug Conjugates for Urothelial Carcinoma.
Journal: JCO precision oncology
Published: May 28, 2026
Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: January 16, 2026
Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.
Journal: BJUI compass
Published: January 02, 2026
Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology.
Journal: Journal for immunotherapy of cancer
Published: November 17, 2025
Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.
Journal: ESMO open
Published: October 31, 2025
Total margin control surgery achieves local control in four high-stage penile squamous cell carcinoma cases.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 19, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Journal: CA: a cancer journal for clinicians
Published: September 15, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 11, 2025
Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration.
Journal: Journal of immunotherapy and precision oncology
Published: July 16, 2025
Clinical perspective on management of key adverse events with sacituzumab govitecan.
Journal: The oncologist
Published: June 24, 2025
Last Updated: 09/26/2026